On December 27, the largest ever acquisition of Abbott had obtained a breakthrough. The Federal Trade Commission The US Federal Trade Commission, FTC) formally approved Abbott laboratories (nyse: ABT) to complete its proposed $25 billion acquisition of st Jude medical company (nyse: STJ).

Abbott and st Jude said the deal would allow st Jude in heart failure treatment equipment, strong advantages in the field of cardiac catheterization and defibrillator and abbott laboratories in coronary artery intervention and valve repair combined advantages, and expected to 2020, will generate $500 million in sales and operating earnings.

The FTC said, stripping business is to keep the purchase will not lead to the meaning of "the two significant damage to the market competition". The agency also warned abbott if it from Advanced Cardiac Therapeutics (Advanced Cardiac Therapeutics) acquired lesions ablation catheter assets assessment. Only 1 st Jude medical company and other companies produce the technique, the FTC has warned that buy the new developers can eliminate extra further in the field of competition.

Last month the European Commission (European appointed the decision about the agreement is stripping a line equipment: st. Jude must handle its Angio - Seal and Femoseal vascular closing device assets, including manufacturing plants in Puerto Rico. Abbott laboratories must be in the treatment of the earlier this year buy Kalila Medical Vado can be turned to the sheath. The two assets will be paid $1 billion into the Terumo.

Abbott said the deal would help it compete with larger rivals medtronic and Boston scientific, because the hospital wants to cut the quantity of its suppliers.